An observational study in T2DM (Type 2 Diabetes Mellitus), sponsored by Chipscreen Biosciences, Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Chipscreen Biosciences, Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 913 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 229 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.
Among the 913 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 34th largest by planned enrollment of the 143 observational ones that give a count, is one of 89 that started in 2026, is one of 143 observational ones, reaches primary completion later than 170 of the 228 other live ones, and was the 831st registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →205 of the 913 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in China, United States, Argentina and 8 more countries
Ages 18+
BrightGene Bio-Medical Technology Co., Ltd. · Sites in China
Ages 18–75
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–75
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
913 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 143 · Phase 2 90 · Phase 3 216 · Phase 4 155
First in 1998; this study’s year is marked. 89 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,550 is above the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 192 across the 769 interventional studies, 556 across the 143 observational. Of the 521 that completed or were terminated, 123 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
448 of 913 have an industry lead sponsor. The 10 most frequent:
Chipscreen Biosciences, Ltd. is the lead sponsor of 42 studies on the registry; 11 are open to participants now.
Chipscreen Biosciences, Ltd. has 7 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
56 of the studies in Diabetes Mellitus, Type 2 with a site in China that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060456Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin | 2027-02 |
| NCT07082114Phase 3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | 2027-02-16 |
| NCT07156500Phase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone | 2027-03-30 |
| NCT07156539Phase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.A Phase 3 Study of HS-20094 in Patients With T2DM | 2027-03-30 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 56 to your calendar (.ics) → With an account.
Among the 913 studies in Diabetes Mellitus, Type 2 with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate the comprehensive clinical efficacy, cardiovascular, renal, and hepatic benefits, as well as the safety of adding Chiglitazar to SGLT-2 inhibitor therapy in adult patients with Type 2 Diabetes Mellitus (T2DM) . The main questions it aims to answer are:
What is the real-world effectiveness of Chiglitazar, when added to an SGLT-2 inhibitor, on glycemic control? What are the effects of this combination therapy on cardiovascular, renal, and hepatic outcomes? What is the overall safety of this treatment regimen?
This is a non-interventional study. Participants will be prescribed Chiglitazar or other oral antidiabetic drugs by their treating physician as part of their routine clinical care. For the purpose of this registry study, data will be collected from their regular medical follow-ups. Participants will:
Attend regular follow-up visits as part of their standard diabetes care. Have data collected from their routine clinical assessments.
T2DM patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with T2DM on a background SGLT-2 inhibitor-based therapy who are newly prescribed Chiglitazar by their treating physician. This cohort includes patients on dual therapy (SGLT-2i + Chiglitazar) or triple therapy (SGLT-2i + Chiglitazar + another oral antidiabetic drug).
Drug: SGLT-2 inhibitor and Chiglitazar
Participants with T2DM on a background SGLT-2 inhibitor-based therapy who are prescribed oral antidiabetic drugs (other than Chiglitazar)
Drug: SGLT-2 inhibitor and Other Oral Antidiabetic Drugs (OADs)
Drug pages: SGLT2 inhibitorsStudies of SGLT2 inhibitorsSGLT2 inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ChiglitazarStudies of ChiglitazarChiglitazar pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Prescribed as an add-on therapy to an SGLT-2 inhibitor-based regimen according to the physician's clinical judgment and routine practice
Any oral antidiabetic drug (other than Chiglitazar) prescribed by the treating physician as an add-on therapy to an SGLT-2 inhibitor-based regimen.
Glycated Hemoglobin (HbA1c)
Change From Baseline in Glycated Hemoglobin (HbA1c) at 6 Months
Time frame: Baseline, 6 Months
N-terminal pro-B-type natriuretic peptide
To assess the change from baseline in N-terminal pro-B-type natriuretic peptide
Time frame: Baseline, 6 Months, 12 Months
High-sensitivity C-reactive Protein
To assess the change from baseline in High-sensitivity C-reactive Protein
Time frame: Baseline, 6 Months, 12 Months
Liver Chemistries: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Total Bilirubin (TBIL), and Gamma-Glutamyl Transferase (GGT).
To assess the change from baseline in Liver Function Test Markers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Total Bilirubin (TBIL), and Gamma-Glutamyl Transferase (GGT).
Time frame: Baseline, 3 Months, 6 Months, 9 Months, 12 Months.
Renal Function Markers: estimated Glomerular Filtration Rate, Urine Albumin-to-Creatinine Ratio, Serum Creatinine, Blood Urea Nitrogen, Uric Acid, and Cystatin C
To assess the change from baseline in markers for chronic kidney disease, including estimated Glomerular Filtration Rate, Urine Albumin-to-Creatinine Ratio, Serum Creatinine, Blood Urea Nitrogen, Uric Acid, and Cystatin C.
Time frame: Baseline, 6 Months, 12 Months.
Resolution Rate of Metabolic Syndrome
Time frame: 6 Months, 12 Months.
Proportion of Patients Achieving Glycemic Control Targets
To assess the percentage of patients reaching predefined Glycated Hemoglobin targets of \<6.5%, \<7.0%, and \<7.5%.
Time frame: 3 Months, 6 Months, 9 Months, 12 Months.
Glycated Hemoglobin
To assess the change from baseline in Glycated Hemoglobin (HbA1c).
Time frame: Baseline, 3 Months, 9 Months, 12 Months.
Fasting Blood Glucose
To assess the change from baseline in fasting blood glucose.
Time frame: Baseline, 3 Months, 6 Months, 9 Months, 12 Months.
Patient-Reported Quality of Life (DSQL) score
To measure the change in patient-reported quality of life using the Diabetes-Specific Quality of Life (DSQL) score.
Time frame: Baseline, 3 Months, 6 Months, 9 Months, 12 Months.
Incidence of Adverse Events
Time frame: Up to 12 months
Medication Costs
To assess the medication costs associated with Type 2 Diabetes.
Time frame: Up to 12 months
Incidence of Major Adverse Cardiovascular Events (MACE)
To assess the number of participants experiencing one or more components of MACE (a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke).
Time frame: Up to 12 months.
non-invasive scores for liver steatosis and fibrosis: Fibrosis-4 Index
Time frame: Baseline, 6 Months,12 Months.
blood pressure (systolic and diastolic)
To assess the change from baseline in blood pressure (systolic and diastolic).
Time frame: Baseline, 3 Months, 6 Months, 9 Months, 12 Months.
body weight
To assess the change from baseline in body weight.
Time frame: Baseline, 3 Months, 6 Months, 9 Months, 12 Months.
waist circumference
To assess the change from baseline in waist circumference.
Time frame: Baseline, 3 Months, 6 Months, 9 Months, 12 Months.
Body Mass Index
To assess the change from baseline in Body Mass Index.
Time frame: Baseline, 3 Months, 6 Months, 9 Months, 12 Months.
Triglycerides(TG)
To assess the change from baseline in Triglycerides(TG)
Time frame: Baseline, 6 Months, 12 Months
Total Cholesterol (TC)
To assess the change from baseline in Total Cholesterol (TC)
Time frame: Baseline, 6 Months, 12 Months
Low-Density Lipoprotein Cholesterol (LDL-C)
To assess the change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C)
Time frame: Baseline, 6 Months, 12 Months
High-Density Lipoprotein Cholesterol (HDL-C)
To assess the change from baseline in High-Density Lipoprotein Cholesterol (HDL-C)
Time frame: Baseline, 6 Months, 12 Months
Non-High-Density Lipoprotein Cholesterol (non-HDL-C)
To assess the change from baseline in Non-High-Density Lipoprotein Cholesterol (non-HDL-C)
Time frame: Baseline, 6 Months, 12 Months
Free Fatty Acids (FFA)
To assess the change from baseline in Free Fatty Acids (FFA)
Time frame: Baseline, 6 Months, 12 Months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jan 2028, 16 months after the start.
Of 170 industry-sponsored observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's planned 16 months is below that.
Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chipscreen Biosciences, Ltd. →